IL10 and neoplasm: Yamazaki et al. [74] reported that higher serum pre-treatment levels of IFN-γ, interleukin 6 (IL-6), and IL-10 were associated with tumor response to nivolumab in melanoma patients and that decreased levels of these cytokines were observed in non-responders.